Literature DB >> 2642382

Maxillary ameloblastoma. A potentially lethal neoplasm.

J K Bredenkamp1, M C Zimmerman, R A Mickel.   

Abstract

Ameloblastomas are benign tumors derived from the odontogenic apparatus. Of these tumors, 80% originate in the mandible, while 20% originate in the maxilla. Six cases of maxillary ameloblastoma treated at the UCLA hospitals are presented; four of these cases showed extensive and destructive tumor growth involving vital structures, including the orbit, base of skull, and parasellar structures. Two of four patients with extensive disease died of their tumors, one, with extensive involvement of the base of the skull, became unavailable for follow-up, and, one year after diagnosis, one is alive with middle cranial fossa disease. A review of the medical literature provides further evidence of the locally aggressive behavior and potentially lethal nature of this tumor. No effective treatment has evolved for extensive ameloblastomas of the maxilla that have invaded surrounding vital structures. When tumor-free surgical margins are not possible, radiation therapy may offer palliation of disease.

Entities:  

Mesh:

Year:  1989        PMID: 2642382     DOI: 10.1001/archotol.1989.01860250101036

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  11 in total

1.  Neuro-ophthalmologic Aspects of Ameloblastoma.

Authors:  P W Brazis; N R Miller; A G Lee; M J Holliday
Journal:  Skull Base Surg       Date:  1995

2.  Ameloblastoma: 25 Year Experience at a Single Institution.

Authors:  Tatyana Milman; Gui-Shuang Ying; Wei Pan; Virginia LiVolsi
Journal:  Head Neck Pathol       Date:  2016-06-07

Review 3.  Ameloblastoma: a clinical review and trends in management.

Authors:  Andrew C McClary; Robert B West; Ashley C McClary; Jonathan R Pollack; Nancy J Fischbein; Christopher F Holsinger; John Sunwoo; A Dimitrios Colevas; Davud Sirjani
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-04-30       Impact factor: 2.503

4.  [Orbital invasion of a maxillary ameloblastoma].

Authors:  M C Herwig; H P Fischer; C E Moore; M D Walsh; J J Olson; J J Beitler; H E Grossniklaus
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

Review 5.  Ameloblastoma and Intracranial Involvement: The Current Challenge of the Radical Surgical Treatment. Comprehensive Review of the Literature and Institution experience.

Authors:  Daniele Armocida; Luigi Valentino Berra; Resi Pucci; Andrea Battisti; Marco Della Monaca; Valentino Valentini; Antonio Santoro
Journal:  J Maxillofac Oral Surg       Date:  2021-09-24

6.  Ameloblastomas of the mandible and maxilla.

Authors:  Ivana D Petrovic; Jocelyn Migliacci; Ian Ganly; Snehal Patel; Bin Xu; Ronald Ghossein; Joseph Huryn; Jatin Shah
Journal:  Ear Nose Throat J       Date:  2018-07       Impact factor: 1.697

Review 7.  Maxillary Ameloblastoma: A Review With Clinical, Histological and Prognostic Data of a Rare Tumor.

Authors:  Zoi Evangelou; Athina Zarachi; Jean Marc Dumollard; Michel Peoc'h; Ioannis Komnos; Ioannis Kastanioudakis; Georgia Karpathiou
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 8.  Maxillary Ameloblastoma with Orbital Involvement: An Institutional Experience and Literature Review.

Authors:  Tatyana Milman; Vivian Lee; Virginia LiVolsi
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2016 Nov/Dec       Impact factor: 1.746

Review 9.  Establishing the natural history and growth rate of ameloblastoma with implications for management: systematic review and meta-analysis.

Authors:  Michael P Chae; Nicolas R Smoll; David J Hunter-Smith; Warren Matthew Rozen
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

Review 10.  Orbital invasion of ameloblastoma: A systematic review apropos of a rare entity.

Authors:  Mohammad-Ali Abtahi; Alireza Zandi; Hassan Razmjoo; Sara Ghaffari; Seyed-Mojtaba Abtahi; Hamidreza Jahanbani-Ardakani; Zahra Kasaei; Samira Kasaei-Koupaei; Sepideh Sajjadi; Seyed-Ali Sonbolestan; Seyed-Hossein Abtahi
Journal:  J Curr Ophthalmol       Date:  2017-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.